All patients (n = 56) | Oral (n = 28) | i.v. (n = 28) | |
---|---|---|---|
Gender (female/male) | 42/14 | 20/8 | 22/6 |
Median age (range) (years) | 33 (23 to 60) | 35 (18 to 60) | |
Median duration of symptoms before treatment (range) (days) | 7 (1 to 35) | 7 (1 to 30) | |
Median total dose MP (range) (grams) | 3.0 (1.5 to 5) | 3.0 (2.8 to 6) | |
Median treatment duration (range) (days) | 3 (3 to 5) | 3 (3 to 6) | |
Median follow-up time (range) (weeks) | 9 (4 to 24) | 9 (4 to 24) | |
Multiple sclerosis before treatment (number of patients) | 13 | 5 | 8 |
Undergoing disease-modifying therapy for MS (number of patients) | 8 | 2 | 6 |
Previous ON in other eye (number of patients) | 8 | 5 | 3 |